Top Markets
Coin of the day
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc.

VIAP
Rank in Stocks #41780
VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily... VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily focused on discovering and advancing therapeutic compounds for cardiovascular and metabolic disorders. The firm is building a portfolio of small-molecule drug candidates designed to tackle the root causes of these health issues, such as vascular inflammation, elevated cholesterol and triglyceride levels, and insulin resistance or diabetes. Notable candidates in their development pipeline include: VIA-3196: A liver-specific thyroid hormone receptor (THR) beta agonist, poised for Phase 1 clinical studies. This drug aims to mitigate dyslipidemia, addressing high LDL cholesterol, elevated triglycerides, and Lp(a) levels. A Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor: Currently in preclinical development for treating type 2 diabetes, with promising potential for weight management and other lipid disorders. VIA-2291: A 5-Lipoxygenase inhibitor that has successfully completed its third Phase 2 clinical trial. Its purpose is to target atherosclerotic plaque, a significant contributor to heart attacks, strokes, and various other vascular diseases. VIA Pharmaceuticals has also forged two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. These collaborations pertain to their THR beta agonist program and several compounds from their preclinical DGAT1 metabolic disorders initiative. Established in 2004, the company's headquarters are located in San Francisco, California.
Share Price
$0.0005
Last synced: 2026-08-11
Market Cap
$10.28K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade VIA Pharmaceuticals, Inc. (VIAP)

Category

Earnings for VIA Pharmaceuticals, Inc. (VIAP)
Earnings in 2026 TTM: 0
According to VIA Pharmaceuticals, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for VIA Pharmaceuticals, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors